Research at ASH 2013 Points the Way Forward for Myeloma Patients

This year's annual meeting of the American Hematological Society (ASH) was truly exhausting, but especially exciting. So many abstracts, so little time!  One had to be a magician to cover major sessions running in parallel. Add to that the cold weather in New Orleans, travel delays, a vast, maze-like, conference center, and you end up with multiple 18-hour days.

ASH 2013 Preview, Part 2: From New Drugs to the Biology of Myeloma

Last week, in Part I of my overview of abstracts released by the American Society of Hematology (ASH) in advance of the group's annual meeting in New Orleans, I focused on combinations using the approved novel agents.

ASH 2013 Preview, Part 1: More Than 100 Interesting and Important Myeloma Abstracts

The ASH 2013 abstracts were released on November 7th.  As usual, there are a staggering number of myeloma abstracts: this year, 830. The IMF team has been reviewing them studiously, trying to identify what is new, interesting, and important. We have identified 131 abstracts worthy of specific comment: 38 oral presentations and 93 posters.

Are Oreo Cookies Really Addictive? Update on 'the Good, Bad, and We're Not Too Sure!'

There is a constant flood of information about food. This is partly because we all eat and someone is always trying to sell us a cookie, organic salad, or whatever we want or crave.  But it is also because there is a lot of new and important information, which can guide our decisions.

Minimal Residual Disease Testing: A New Way Forward

There are two important news items to report this week.  First, an article in Blood reports that current MRD testing for myeloma in the US is producing quite erratic results.